Also, PSMA-targeting radioligand therapy, although traditionally used in prostate cancer, has been explored for brain tumors via intra-arterial administration, including meningiomas, where PSMA is expressed in tumor-associated vasculature. The gene discussed is FOLH1; the disease is prostate carcinoma.